Developer docs
API playgroundTry for free, no card

Search company profiles

Soleno Therapeutics

Full company profile

uuid0000k6v

Namestring
Soleno Therapeutics
Legal namestring
Soleno Therapeutics, Inc.
Websiteurl
soleno.life
Company typeenum
Public
Founded yearint
2004
Descriptiontext

Soleno Therapeutics is a clinical-stage-to-commercial biopharmaceutical company focused on developing and commercializing therapeutics for rare genetic disorders, with a singular focus on Prader-Willi syndrome (PWS), a genetic condition affecting an estimated 350,000-400,000 people globally with a birth incidence of approximately 1 in 15,000. The company's lead and only commercial product is VYKAT XR (diazoxide choline) extended-release tablets, a once-daily oral formulation that received FDA approval on March 26, 2025 as the first and only treatment indicated for hyperphagia (insatiable hunger) in PWS patients aged 4 and older. The product generated $190 million in revenue in the post-approval period and is protected by formulation patents extending into the 2040s.

The underlying technology is a proprietary extended-release formulation of diazoxide choline designed to deliver sustained drug exposure via once-daily oral dosing, differentiating it from legacy immediaterelease diazoxide and supporting durable reductions in hyperphagia and behavioral symptoms as demonstrated through three years of Phase III follow-up data (p<0.0001 across all six behavioral domains). Soleno commercializes VYKAT XR through a sales-led, physician-prescribed specialty pharmacy model in the United States, targeting endocrinologists and genetic specialists treating PWS patients. The company supports adoption through medical affairs, patient support programs, and partnerships with the three major PWS advocacy organizations (Foundation for Prader-Willi Research, PWSA-USA, IPWSO). An EU marketing application was filed but withdrawn in April 2026.

Soleno was founded in California in 2004, headquartered in Redwood City, CA, and listed on Nasdaq under ticker SLNO until May 2026, when it was acquired by Neurocrine Biosciences for approximately $2.9 billion ($53.00 per share, with roughly 88.9% of shares tendered). Soleno now operates as a wholly owned subsidiary of Neurocrine. During 2025-2026 the company faced multiple securities class action lawsuits alleging misrepresentation of VYKAT XR safety and commercial viability, which remained a residual risk at the time of acquisition.

Short descriptiontext

Soleno Therapeutics is a US biopharmaceutical company that develops and commercializes VYKAT XR (diazoxide choline extended-release), the first and only FDA-approved once-daily oral treatment for hyperphagia in Prader-Willi syndrome patients aged 4 and older. Now a wholly owned Neurocrine Biosciences subsidiary.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersRedwood City, United States
HQ citystring
Redwood City
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
Rare disease therapeutics, Prader-Willi syndrome treatment, Orphan drug development, Specialty pharmaceuticals, Extended-release formulations
Industry1 code
PRIMARYHLAIAIAJ
Rare Endocrine & Growth Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
NAICS code1 code
  • Offices of Optometrists62132
SIC code1 code
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
Product category
Rare Disease Therapeutics
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1VYKAT XR Product Sales
TypeOne Time License
Description

Direct product sales of VYKAT XR (diazoxide choline extended-release tablets) for the treatment of hyperphagia in Prader-Willi syndrome patients. Generated $190 million in revenue in 2024/2025 following FDA approval in March 2025.

pharmaphorum.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1VYKAT XR
Description

Once-daily oral treatment (diazoxide choline) for hyperphagia in individuals aged 4 and older with Prader-Willi syndrome

soleno.life
+1 more record
Core offering1 text field

Soleno Therapeutics develops and commercializes VYKAT XR (diazoxide choline extended-release tablets), an FDA-approved once-daily prescription therapy indicated to treat hyperphagia in patients aged 4 and older with Prader-Willi syndrome (PWS). The company focuses exclusively on rare disease therapeutics, with VYKAT XR being the first and only FDA-approved treatment specifically for hyperphagia in PWS. Following its acquisition by Neurocrine Biosciences in May 2026, Soleno operates as a wholly owned subsidiary.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Phase III data demonstrated statistically significant and sustained improvements in hyperphagia and all six behavioral domains (p<0.0001 at all time points) through three years
+1 more record
Product overview1 text field

Soleno Therapeutics is a biopharmaceutical company focused on rare diseases, primarily developing and commercializing therapeutics for Prader-Willi syndrome (PWS). The company's single commercial product is VYKAT XR (diazoxide choline) extended-release tablets, an FDA-approved once-daily oral treatment for hyperphagia in patients aged 4 and older with PWS. DCCR is the same drug compound referred to by its clinical development name. Following acquisition by Neurocrine Biosciences in 2026, Soleno operates as a wholly owned subsidiary.

Product and service1 record
1VYKAT XR
CategoryRare Disease Therapeutics
Description

VYKAT XR (diazoxide choline extended-release tablets) is a once-daily prescription therapy FDA-approved on March 26, 2025 to treat hyperphagia in patients aged 4 and older with Prader-Willi syndrome. It is the first and only FDA-approved therapy indicated for hyperphagia in PWS and is sold through specialty pharmacies and prescribing physicians.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2026-04-06
Description

Neurocrine Biosciences acquired Soleno Therapeutics for approximately $2.9 billion in May 2026. The acquisition added VYKAT XR to Neurocrine's portfolio, expanding into endocrinology and rare diseases. Soleno became a wholly owned subsidiary of Neurocrine.

Strategic tierMinorTypeOthers
Description

Patient advocacy organization collaborating with Soleno to advance awareness and advocacy in the PWS community. The foundation supports research and provides resources for patients and families.

Strategic tierMinorTypeOthers
Description

National patient advocacy organization providing support, information, and resources for people with PWS and caregivers. Soleno supports their efforts to raise awareness of the condition.

Strategic tierMinorTypeOthers
Description

Global advocacy organization serving the international PWS community. Soleno collaborates with IPWSO to advance global awareness and support for patients and families.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Global rare disease biopharma with a multi-asset portfolio of orphan drugs targeting genetic and metabolic conditions. Comparable in commercial rare disease infrastructure, payer engagement, and product expansion strategy for high-need genetic disorders.

TypeBroad incumbent
Description

Specialty pharma with a dedicated rare disease division commercializing orphan therapies globally. Comparable in rare disease commercial infrastructure and physician-led specialty distribution.

TypeBroad incumbent
Description

Large biopharma with a meaningful rare disease franchise (e.g., Eylea, Inmazeb) alongside broader therapeutic areas. Comparable in capabilities to develop and commercialize high-value orphan biologics for underserved populations.

TypeBroad incumbent
Description

Established leader in rare disease biopharma, now part of AstraZeneca, with a broad portfolio of approved orphan therapies. Comparable in regulatory, payer, and global rare disease commercialization capabilities, though at significantly larger scale.

TypeEmerging player
Description

Clinical- and early-commercial-stage rare disease biopharma targeting genetic diseases. Comparable in therapeutic area focus and small-cap orphan drug development economics.

TypeDirect peer
Description

Commercial-stage rare disease biopharma focused on genetic and metabolic disorders, with multiple approved orphan therapies. Highly comparable to Soleno in patient population focus, regulatory strategy, and commercial model for ultra-rare conditions.

TypeEmerging player
Description

Antisense-based rare disease biopharma with multiple approved and pipeline orphan assets. Comparable in developing novel therapies for genetic disorders with high unmet need and small patient populations.

TypeBroad incumbent
Description

Commercial-stage biopharma with a portfolio of high-value therapies for serious rare genetic diseases (e.g., cystic fibrosis, sickle cell). Comparable in pricing power, payer engagement, and durable orphan exclusivity economics.

TypeDirect peer
Description

Commercial-stage rare disease biopharma with a single approved CNS product generating strong revenue. Closely mirrors Soleno's small-cap, single-asset, rare-disease commercial model and prescriber-driven distribution approach.

TypeDirect peer
Description

Rare disease biopharma developing therapies for genetic and metabolic conditions with FDA-approved orphan products. Comparable in target therapeutic areas (rare metabolic/genetic disorders) and specialty commercial motion.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors9 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Soleno Therapeutics

Rare Disease Therapeuticssoleno.life

Soleno Therapeutics is a US biopharmaceutical company that develops and commercializes VYKAT XR (diazoxide choline extended-release), the first and only FDA-approved once-daily oral treatment for hyperphagia in Prader-Willi syndrome patients aged 4 and older. Now a wholly owned Neurocrine Biosciences subsidiary.

What Soleno Therapeutics does

Soleno Therapeutics is a clinical-stage-to-commercial biopharmaceutical company focused on developing and commercializing therapeutics for rare genetic disorders, with a singular focus on Prader-Willi syndrome (PWS), a genetic condition affecting an estimated 350,000-400,000 people globally with a birth incidence of approximately 1 in 15,000. The company's lead and only commercial product is VYKAT XR (diazoxide choline) extended-release tablets, a once-daily oral formulation that received FDA approval on March 26, 2025 as the first and only treatment indicated for hyperphagia (insatiable hunger) in PWS patients aged 4 and older. The product generated $190 million in revenue in the post-approval period and is protected by formulation patents extending into the 2040s.

The underlying technology is a proprietary extended-release formulation of diazoxide choline designed to deliver sustained drug exposure via once-daily oral dosing, differentiating it from legacy immediaterelease diazoxide and supporting durable reductions in hyperphagia and behavioral symptoms as demonstrated through three years of Phase III follow-up data (p<0.0001 across all six behavioral domains). Soleno commercializes VYKAT XR through a sales-led, physician-prescribed specialty pharmacy model in the United States, targeting endocrinologists and genetic specialists treating PWS patients. The company supports adoption through medical affairs, patient support programs, and partnerships with the three major PWS advocacy organizations (Foundation for Prader-Willi Research, PWSA-USA, IPWSO). An EU marketing application was filed but withdrawn in April 2026.

Soleno was founded in California in 2004, headquartered in Redwood City, CA, and listed on Nasdaq under ticker SLNO until May 2026, when it was acquired by Neurocrine Biosciences for approximately $2.9 billion ($53.00 per share, with roughly 88.9% of shares tendered). Soleno now operates as a wholly owned subsidiary of Neurocrine. During 2025-2026 the company faced multiple securities class action lawsuits alleging misrepresentation of VYKAT XR safety and commercial viability, which remained a residual risk at the time of acquisition.

Soleno Therapeutics firmographics

Firmographics
Name
Soleno Therapeutics
Legal name
Soleno Therapeutics, Inc.
Website
https://soleno.life
Company type
Public
Founded year
2004
Operating status
Acquired
Headcount range
101–250 employees
Short description
Soleno Therapeutics is a US biopharmaceutical company that develops and commercializes VYKAT XR (diazoxide choline extended-release), the first and only FDA-approved once-daily oral treatment for hyperphagia in Prader-Willi syndrome patients aged 4 and older. Now a wholly owned Neurocrine Biosciences subsidiary.
Ownership category
akta.pro rank

Soleno Therapeutics industry classification

Industry
Product category
Rare Disease Therapeutics
NAICS
Offices of Optometrists (62132)
SIC
Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
akta.pro industry
PRIMARYHLAIAIAJ
Rare Endocrine & Growth Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals

Keywords

  • Rare disease therapeutics
  • Prader-Willi syndrome treatment
  • Orphan drug development
  • Specialty pharmaceuticals
  • Extended-release formulations

Where Soleno Therapeutics is headquartered

Location

Headquarters

HQ city
Redwood City
HQ country
United States
HQ region
North America

Offices3 records

Markets served

Soleno Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. VYKAT XR Product Sales: Direct product sales of VYKAT XR (diazoxide choline extended-release tablets) for the treatment of hyperphagia in Prader-Willi syndrome patients. Generated $190 million in revenue in 2024/2025 following FDA approval in March 2025.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Soleno Therapeutics product offering

Product offering

Core offering

Soleno Therapeutics develops and commercializes VYKAT XR (diazoxide choline extended-release tablets), an FDA-approved once-daily prescription therapy indicated to treat hyperphagia in patients aged 4 and older with Prader-Willi syndrome (PWS). The company focuses exclusively on rare disease therapeutics, with VYKAT XR being the first and only FDA-approved treatment specifically for hyperphagia in PWS. Following its acquisition by Neurocrine Biosciences in May 2026, Soleno operates as a wholly owned subsidiary.

Product overview

Soleno Therapeutics is a biopharmaceutical company focused on rare diseases, primarily developing and commercializing therapeutics for Prader-Willi syndrome (PWS). The company's single commercial product is VYKAT XR (diazoxide choline) extended-release tablets, an FDA-approved once-daily oral treatment for hyperphagia in patients aged 4 and older with PWS. DCCR is the same drug compound referred to by its clinical development name. Following acquisition by Neurocrine Biosciences in 2026, Soleno operates as a wholly owned subsidiary.

Differentiator

Problem solved

Functional benefit

Brands

  • VYKAT XR: Once-daily oral treatment (diazoxide choline) for hyperphagia in individuals aged 4 and older with Prader-Willi syndrome
  • Soleno Medical Affairs

Products and services

  • VYKAT XR VYKAT XR (diazoxide choline extended-release tablets) is a once-daily prescription therapy FDA-approved on March 26, 2025 to treat hyperphagia in patients aged 4 and older with Prader-Willi syndrome. It is the first and only FDA-approved therapy indicated for hyperphagia in PWS and is sold through specialty pharmacies and prescribing physicians.

Quantifiable outcome

  • Phase III data demonstrated statistically significant and sustained improvements in hyperphagia and all six behavioral domains (p<0.0001 at all time points) through three years
  • +1 more outcomes

Companies that use Soleno Therapeutics

Customer profile

Segments1 record

Ideal customer profiles1 record

Soleno Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Soleno Therapeutics partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered flagship and minor.

  • Neurocrine BiosciencesflagshipStrategic or Co-development Partner · 6 April 2026Neurocrine Biosciences acquired Soleno Therapeutics for approximately $2.9 billion in May 2026. The acquisition added VYKAT XR to Neurocrine's portfolio, expanding into endocrinology and rare diseases. Soleno became a wholly owned subsidiary of Neurocrine.
  • Foundation for Prader-Willi ResearchminorOthersPatient advocacy organization collaborating with Soleno to advance awareness and advocacy in the PWS community. The foundation supports research and provides resources for patients and families.
  • Prader-Willi Syndrome Association USAminorOthersNational patient advocacy organization providing support, information, and resources for people with PWS and caregivers. Soleno supports their efforts to raise awareness of the condition.
  • International Prader-Willi Syndrome OrganizationminorOthersGlobal advocacy organization serving the international PWS community. Soleno collaborates with IPWSO to advance global awareness and support for patients and families.

Scale indicators6 records

Recent moves6 records

Expansion highlights4 records

Soleno Therapeutics competitors and assessment

Company assessment

Direct peers

  • BioMarin Pharmaceutical: Global rare disease biopharma with a multi-asset portfolio of orphan drugs targeting genetic and metabolic conditions. Comparable in commercial rare disease infrastructure, payer engagement, and product expansion strategy for high-need genetic disorders.
  • Ultragenyx Pharmaceutical: Commercial-stage rare disease biopharma focused on genetic and metabolic disorders, with multiple approved orphan therapies. Highly comparable to Soleno in patient population focus, regulatory strategy, and commercial model for ultra-rare conditions.
  • Harmony Biosciences: Commercial-stage rare disease biopharma with a single approved CNS product generating strong revenue. Closely mirrors Soleno's small-cap, single-asset, rare-disease commercial model and prescriber-driven distribution approach.
  • Travere Therapeutics: Rare disease biopharma developing therapies for genetic and metabolic conditions with FDA-approved orphan products. Comparable in target therapeutic areas (rare metabolic/genetic disorders) and specialty commercial motion.

Broad incumbents

  • Recordati Rare Diseases: Specialty pharma with a dedicated rare disease division commercializing orphan therapies globally. Comparable in rare disease commercial infrastructure and physician-led specialty distribution.
  • Regeneron Pharmaceuticals: Large biopharma with a meaningful rare disease franchise (e.g., Eylea, Inmazeb) alongside broader therapeutic areas. Comparable in capabilities to develop and commercialize high-value orphan biologics for underserved populations.
  • Alexion (AstraZeneca Rare Disease): Established leader in rare disease biopharma, now part of AstraZeneca, with a broad portfolio of approved orphan therapies. Comparable in regulatory, payer, and global rare disease commercialization capabilities, though at significantly larger scale.
  • Vertex Pharmaceuticals: Commercial-stage biopharma with a portfolio of high-value therapies for serious rare genetic diseases (e.g., cystic fibrosis, sickle cell). Comparable in pricing power, payer engagement, and durable orphan exclusivity economics.

Emerging players

  • BridgeBio Pharma: Clinical- and early-commercial-stage rare disease biopharma targeting genetic diseases. Comparable in therapeutic area focus and small-cap orphan drug development economics.
  • Ionis Pharmaceuticals: Antisense-based rare disease biopharma with multiple approved and pipeline orphan assets. Comparable in developing novel therapies for genetic disorders with high unmet need and small patient populations.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Soleno Therapeutics social profiles

Digital presence

Soleno Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Soleno Therapeutics leadership team

Management profile

Number of profiles

Profiles1 record

Soleno Therapeutics subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Soleno Therapeutics funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Soleno Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Soleno Therapeutics

What does Soleno Therapeutics do?

Soleno Therapeutics develops and commercializes VYKAT XR (diazoxide choline extended-release tablets), an FDA-approved once-daily prescription therapy indicated to treat hyperphagia in patients aged 4 and older with Prader-Willi syndrome (PWS). The company focuses exclusively on rare disease therapeutics, with VYKAT XR being the first and only FDA-approved treatment specifically for hyperphagia in PWS. Following its acquisition by Neurocrine Biosciences in May 2026, Soleno operates as a wholly owned subsidiary.

Is Soleno Therapeutics a public or private company?

Soleno Therapeutics is a public company. It is classified as corporate owned and is currently acquired.

When was Soleno Therapeutics founded?

Soleno Therapeutics was founded in 2004. It employs 101 to 250 people.

Where is Soleno Therapeutics based?

Soleno Therapeutics is headquartered in Redwood City, United States, in the North America region.

How does Soleno Therapeutics make money?

One revenue line is on record: VYKAT XR Product Sales.

Who are Soleno Therapeutics's main competitors?

Direct peers on record are BioMarin Pharmaceutical, Ultragenyx Pharmaceutical, Harmony Biosciences and Travere Therapeutics. Broad incumbents are Recordati Rare Diseases, Regeneron Pharmaceuticals, Alexion (AstraZeneca Rare Disease) and Vertex Pharmaceuticals. Emerging players are BridgeBio Pharma and Ionis Pharmaceuticals.

Does Soleno Therapeutics have an API?

No public API is recorded for Soleno Therapeutics.

What industry is Soleno Therapeutics in?

Soleno Therapeutics's product category is Rare Disease Therapeutics. Its primary akta.pro industry code is HLAIAIAJ, Rare Endocrine & Growth Disorder Therapies. Its NAICS code is 62132 and its SIC code is 5122.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
EIN PresswireUnicycive Therapeutics Appoints Meredith Manning to Board of DirectorsUnicycive Therapeutics appointed Meredith Manning to its Board of Directors, bringing over 25 years of biopharmaceutical commercialization experience. She will serve on the Audit, Compensation, and Nominating and Corporate Governance Committees, chairing the latter. The appointment comes as the company advances its lead product OLC toward potential approval.TradingViewNews by Dow Jones Newswires on TradingView, 2026-09-26Biotech stocks surged this year, with IBB up 24% and XBI up 28%, driven by therapeutic breakthroughs and M&A. Panelists expect continued M&A and AI-driven drug discovery, while noting tech sector rotation risks. Upcoming trial readouts include Librexia-AF and Summit's HARMONi-3.GurufocusKuehn Law Encourages Investors of Soleno Therapeutics, Inc. to CKuehn Law is investigating whether Soleno Therapeutics officers and directors breached fiduciary duties by concealing safety concerns in its DCCR Phase 3 trial. The lawsuit alleges the company downplayed excess fluid retention risks, which could have reduced commercial viability and led to adverse regulatory and reputational consequences.PR NewswireKuehn Law Encourages Investors of Soleno Therapeutics, Inc. to Contact Law FirmKuehn Law is investigating Soleno Therapeutics for alleged breaches of fiduciary duties, claiming the company concealed safety risks in its DCCR Phase 3 trial for Prader-Willi syndrome. The lawsuit asserts the drug posed greater risks than disclosed, leading to lower commercial viability and undisclosed risks after launch. Shareholders who purchased before March 26, 2025, are urged to contact the firm.pharmaphorumNeurocrine receives FDA IND Acceptance for Alzheimer’s Ph2Neurocrine Biosciences received FDA IND acceptance for a Phase 2 study of NBI-1117567 for Alzheimer's cognition, in partnership with Nxera Pharma. The company will pay Nxera a $10 million milestone payment under their 2021 agreement, which includes up to $2.6 billion in future milestones and royalties.Quiver QuantitativeSoleno Therapeutics Stock (SLS) Opinions on REGAL Trial Anticipation | SLS Stock NewsSoleno Therapeutics is approaching a pivotal 80-event milestone in its REGAL study for acute myeloid leukemia, generating significant social media anticipation and trading volatility. Institutional investors have actively adjusted their positions, with major firms like State Street Corp, Anson Funds Management LP, and BlackRock Inc. adding substantial shares in the most recent quarter.AInvestIs NBIX Stock a Buy as Fast Growth Meets a Premium Sales Valuation?Neurocrine Biosciences reported strong second-quarter 2026 results with revenue rising 39% to $959 million and adjusted earnings per share increasing 73%, driven by its Ingrezza and Crenessity products. The company is diversifying its portfolio through the acquisition of Soleno Therapeutics, which added Vykat XR to its lineup. However, analysts note valuation premiums and execution risks, including competition from Teva Pharmaceutical and Bristol Myers Squibb, leading to a 'Hold' recommendation.StocktwitsNBIX Stock Slips As $2.9B Soleno Deal Triggers Fresh Safety WarningsThe Foundation for Prader-Willi Research has recommended that doctors monitor patients on Neurocrine Biosciences' VYKAT XR for potential heart and breathing problems, following the company's $2.9 billion acquisition of Soleno Therapeutics and associated safety warnings. Reports indicate that there have been seven deaths and over 100 serious adverse events related to the drug since its launch. The foundation urges safety precautions for patients, emphasizing the necessity of weighing the drug's benefits against its risks.Tech TimesVykat XR: Seven Deaths Spur Physician Alert for First-Ever PWS Hunger DrugA physician coalition issued a safety alert for Vykat XR, the first drug for Prader-Willi syndrome hyperphagia, after seven deaths and over 100 serious adverse events were reported to the FDA. The alert does not call for stopping the drug but urges rigorous screening for severe obesity, cardiac disease, and sleep apnea. The FDA has not yet issued a safety communication.The Motley FoolNeurocrine (NBIX) Q2 2026 Earnings Call TranscriptNeurocrine Biosciences reported Q2 2026 total revenue of $950 million, representing nearly 40% year-over-year growth driven by strong commercial performance from INGREZZA ($716M), CRENESSITY ($184M), and the newly acquired VYKAT XR franchise ($54M recognized). The company completed its $2.9 billion acquisition of Soleno Therapeutics in May 2026, ending the quarter with $500 million in cash and zero debt, and raised full-year INGREZZA guidance to $2.825-$2.875 billion. Management highlighted progress toward multiple Phase 3 clinical catalysts expected in H2 2027, including osavampator for major depressive disorder and direclidine for schizophrenia, positioning the company for continued growth as it evolves from a single-product to multiproduct commercial-stage entity.